Venus Remedies secures in-licensing rights from Infex Therapeutics to develop and commercialize MET-X in India

MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies

Glenmark Pharmaceuticals USA launches Epinephrine Injection USP

This launch of Epinephrine Injection multiple-dose Vial is eligible for 180 days of CGT exclusivity under section 505(j)(5)(B)(v) of the FD&C Act.

Cadila Pharmaceuticals opens advanced pharmaceutical warehouse

FDA grants EUA to Aptitude’s Covid/flu multiplex test for OTC use

Senores Pharmaceuticals acquires ANDA for Roflumilast 250 mcg and 500 mcg tablets

European Commission approves Biocon Biologics' Ustekinumab Biosimilar

YESINTEK, is intended for the treatment of adults and children with plaque psoriasis and adults with psoriatic arthritis or Crohn's disease

Merck’s Welireg receives European approval for two indications

WELIREG is the first and only oral hypoxia-inducible factor-2 alpha inhibitor approved in the European Union

Sun Pharma amongst top 5% of global pharmaceutical companies in S&P Global Sustainability Yearbook 2025

This Yearbook aims to distinguish those companies that have demonstrated strengths in corporate sustainability

Glenmark Pharmaceuticals USA launches Clindamycin Phosphate Foam, 1%

Glenmark’s Clindamycin Phosphate Foam, 1% is bioequivalent and therapeutically equivalent to Evoclin Foam, 1%, of Mylan Pharmaceuticals.

IOL Chemicals and Pharmaceuticals reports Q3 FY25 revenue at Rs. 527.37 Cr

Total Income during Q3 FY25 stood at Rs. 527.37 crore as compared to Rs. 528.77 crore in Q3 FY24